



Paris, 01/30/2025

Press release

A new implantable biomaterial for bone reconstruction that is completely resorbable

Start-up Pegmatiss Biotech and Erganeo have signed an exclusive licence for the use of an implantable biomaterial that is completely resorbable, designed for dental and orthopaedic regenerative bone medicine.

Many solutions have been developed in regenerative medicine to promote tissue reconstruction. But the problem has always been the risk of the material being rejected by the human body. This was the problem on which a team led by Prof Didier Lutomski (Sorbonne Paris North University, URIT – the Tissue Engineering Research Group) focused in their work on developing a new bone substitute for use in regenerative medicine, the idea being to improve tissue reconstruction.

The substitute was developed as an implantable composite biomaterial made from a bioresorbable elastomer and natural allogeneic bone particles. It therefore has the special quality of being bioresorbable and well tolerated by the human body. This technological innovation is particularly useful in the field of bone regeneration, as well as in dental surgery and orthopaedic surgery.

Erganeo wanted to leverage this innovation by filing and managing a patent¹ in 2020, then subjecting the project to DeepTech maturing over nearly three years in order to scale the product up to the industrial development stage. *“Erganeo’s role in leveraging this technology was key – it involved custom support right from the start of the project up to the transfer stage. A perfect example of how a SATT (technology transfer acceleration company) can contribute to leveraging the benefits of innovation, working alongside the team of researchers whose remarkable efforts have enabled us to envisage the industrial leveraging of a new innovative solution on the medical market”*, says Naceur Tounekti, CEO of Erganeo.

This impetus continued with the birth of start-up Pegmatiss Biotech in October 2023. It was co-founded by Prof Didier Lutomski, Dr Tewfik Kadri and Ikram Mesmoudi, three specialists in tissue engineering, with a focus on biomaterials in particular. Pegmatiss Biotech and Erganeo then signed an exclusive operating licence on 10 December 2024 enabling the start-up to finalise a proof of concept in early 2025, before entering the preclinical and clinical phases, with market launch planned for 2029. The first industrial partners have already shown interest in developing and distributing this solution, signalling healthy prospects for the years ahead.

¹ Sorbonne Paris North University, French centre for scientific research, Ministry of the Armed Forces, Paris Cité University, OST Développement laboratory



ERG\NEO

L'AVENIR EST FAIT D'AUDACE



About Erganeo – www.erganeo.com

Erganeo is a French tech transfer company specialises in breakthrough innovations (deep tech) with a major societal impact. We invest early in the game to secure researchers' newest inventions before they are transferred to companies or before start-ups are founded, across a wide range of scientific fields. Erganeo aims to accelerate and simplify links between research and industry for the benefit of society. To do so, we finance and support the new generation of French researchers and entrepreneurs on the road to international recognition and success. As a member of the SATT Network, Erganeo draws on the Ile-de-France network in building the foundations of a better tomorrow, tapping into a talent pool of over 20,000 researchers across 350 cutting-edge, leading laboratories. Since it was founded, Erganeo has invested over €44m, thus contributing to the signing of 120 licensing agreements with companies of all sizes and setting up 34 start-ups.

Press contact: Caroline Pontifice - Communication and Marketing Manager – caroline.pontifice@erganeo.com

About Pegmatiss Biotech – www.pegmatiss.com

Pegmatiss Biotech is a spin-off of the Tissue Engineering Research Group. It was created on 31 October 2023 within the framework of the finished product maturing programme supported by technology transfer acceleration company Erganeo. The company leverages research conducted by the group, enabling the industrial production of a bone biomaterial designed and patented by the laboratory. PegmaTiss BioTech is designing and developing a completely resorbable implantable medical device to promote bone regeneration, for use in both dentistry and orthopaedics.

Press contact: Tewfik KADRI – Co-founder and Chairman – tewfik.kadri@pegmatiss.com